These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Follicular lymphoma: 2012 update on diagnosis and management. Freedman A Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911 [TBL] [Abstract][Full Text] [Related]
3. Follicular lymphoma: 2014 update on diagnosis and management. Freedman A Am J Hematol; 2014 Apr; 89(4):429-36. PubMed ID: 24687887 [TBL] [Abstract][Full Text] [Related]
4. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Brandt L; Kimby E; Nygren P; Glimelius B; Acta Oncol; 2001; 40(2-3):213-23. PubMed ID: 11441933 [TBL] [Abstract][Full Text] [Related]
5. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Moos M; Schulz R; Martin S; Benner A; Haas R Leukemia; 1998 Dec; 12(12):1971-6. PubMed ID: 9844927 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390 [TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949 [TBL] [Abstract][Full Text] [Related]
9. Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? Northup JK; Gadre SA; Ge Y; Lockhart LH; Velagaleti GV Eur J Haematol; 2007 Feb; 78(2):152-6. PubMed ID: 17313561 [TBL] [Abstract][Full Text] [Related]
10. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
12. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845 [TBL] [Abstract][Full Text] [Related]
14. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Czuczman MS; Grillo-López AJ; McLaughlin P; White CA; Saleh M; Gordon L; LoBuglio AF; Rosenberg J; Alkuzweny B; Maloney D Ann Oncol; 2001 Jan; 12(1):109-14. PubMed ID: 11249036 [TBL] [Abstract][Full Text] [Related]
16. Current treatment and immunotherapy of Hodgkin's lymphoma. Klimm B; Schnell R; Diehl V; Engert A Haematologica; 2005 Dec; 90(12):1680-92. PubMed ID: 16330443 [TBL] [Abstract][Full Text] [Related]
17. The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Naparstek E Curr Hematol Malig Rep; 2006 Dec; 1(4):220-9. PubMed ID: 20425317 [TBL] [Abstract][Full Text] [Related]
18. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma. Kruger PC; Cooney JP; Turner JH Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193 [TBL] [Abstract][Full Text] [Related]
19. Rituximab maintenance versus retreatment in follicular lymphoma. Palla AR; Hamadani M Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794 [TBL] [Abstract][Full Text] [Related]